ArticleCytotechnology2014
Production, purification and titration of a lentivirus-based vector for gene delivery purposes.
Article in Cytotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 78 citations in OpenAlex.
- Overcoming lentiviral delivery limitations in hard-to-transduce suspension cells for genome-wide CRISPR screening.Molecular therapy. Advances · 2026Article
- Novel IL13RA2-targeted immunocytokines exhibit superior antitumor activities.Acta pharmacologica Sinica · 2025Article
- Long noncoding RNA hottip maintained skeletal homeostasisNon-coding RNA research · 2025Article
- An optimizing lentiviral titer determination assay based on Raji cells.American journal of translational research · 2025Article
- Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53.Frontiers in pharmacology · 2025Article
- Phosphoproteomic Profiling Reveals mTOR Signaling in Sustaining Macrophage Phagocytosis of Cancer Cells.Cancers · 2024Article
- Engineering lentivirus envelope VSV-G for liver targeted delivery of IDOL-shRNA to ameliorate hypercholesterolemia and atherosclerosis.Molecular therapy. Nucleic acids · 2024Article
- Article
- Detection of Hypoxia in 2D and 3D Cell Culture Systems Using Genetically Encoded Fluorescent Hypoxia Sensors.Methods in molecular biology (Clifton, N.J.) · 2024Article
- ACE2-Decorated Virus-Like Particles Effectively Block SARS-CoV-2 Infection.International journal of nanomedicine · 2024Article
- Proliferation-associated 2G4 P48 is stabilized by malignant T-cell amplified sequence 1 and promotes the proliferation of head and neck squamous cell carcinoma.Journal of dental sciences · 2023Article
- An ex vivo Model of Paired Cultured Hippocampal Neurons for Bi-directionally Studying Synaptic Transmission and Plasticity.Bio-protocol · 2023Article
- Pseudotyped Viruses.Advances in experimental medicine and biology · 2023Article
- Jianpi Yangzheng Xiaozheng decoction alleviates gastric cancer progression via suppressing exosomal PD-L1.Frontiers in pharmacology · 2023Article
- G-Quadruplex Linked DNA Guides Selective Transfection into Nucleolin-Overexpressing Cancer Cells.Pharmaceutics · 2022Article
- c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance.Cell death & disease · 2022Article
- miR-16-5p Is a Novel Mediator of Venous Smooth Muscle Phenotypic Switching.Journal of cardiovascular translational research · 2022Article
- Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy.Science advances · 2022Article
- Studying Cell Polarity Dynamics During Cancer Initiation Using Inducible 3D Organotypic Cultures.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral vectors are valuable tools to deliver genetic materials into cells. Vectors derived from human immunodeficiency virus type 1 are being widely used for gene delivery, mainly because they are able to transduce both dividing and non-dividing cells which leads to stable and long term gene expression. In addition, these types of vectors are safe, with low toxicity, high stability and cell type specificity. Therefore, this work was aimed to produce lentivirus-based vector using a three-plasmid system. To produce this system, the eGFP marker gene was cloned into the plasmid pWPXLd. Subsequently, this vector plasmid, along with packaging plasmids, psPAX2 and envelope plasmid, pMD2.G, was co-transfected into packaging cell line (293T) using calcium phosphate method. 48 h post transfection, the constructed viral vector was harvested, purified and concentrated and stored at -80 °C for next experiments. The titration of the vector was carried out, using ELISA, flowcytometry, and fluorescent microscopy. Finally, transduction of HEK-293T, CHO, HepG2, MCF-7, MEFs and Jurkat cell lines was carried out with indicated cell numbers and multiplicities of infections of the vector in the presence of polybrene. Using this system, high titer lentivirus at titers of up to 2 × 10(8) transducing units/ml (TU/ml) was successfully generated and its transduction efficacy was improved by seven to over 20-fold in various cell types. We demonstrate the applicability of this vector for the efficient transduction of dividing and non-dividing cells, including HEK-293T, CHO, HepG2, MCF-7, MEFs and Jurkat cell line. Transduction efficiency yielded titers of (6.3 ± 1.2) 10(5) TU/ml. Furthermore, lentivirus transferred transgene was expressed at high level in the target cells and expression was followed until 90 days after transduction. Thus, the vector generated in this work, might be able to deliver the transgene into a wide range of mammalian cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.